INDUSTRY

INDIANAPOLIS--The Indiana Proteomics Consortium has officially changed its name to Inproteo. The new name incorporates the abbreviation for its location -- Indiana -- and suggests its industry -- proteomics. Inproteo is also incorporating a new look to its logo and website along with the new name. "The new name suggests where we are and what we do," said John Hurrell, Inproteo's President. "It also implies that we are a commercial venture -- our research is meant to have an economic impact." Founded in early 2002, Inproteo is a unique partnership between Indiana University, Purdue University and Eli Lilly and Company. Inproteo focuses the strengths of these institutions in analytical chemistry and pharmaceutical R&D on the development of new and innovative proteomic discovery tools and methods. In turn, this research will be commercialized through the creation of new companies, development of joint ventures or the establishment of licensing partnerships. The company has already filed 19 patents within its first year. "Advances in proteomics will revolutionize life sciences diagnostics and analysis and the pharmaceutical industry in particular," said Hurrell. "Bringing the intellectual firepower of IU, Purdue and Eli Lilly to bear on scientific challenges in this field ensures that Inproteo will be on the forefront." Inproteo is an example of a successful collaboration between academia and the private sector, as emphasized by the Central Indiana Life Sciences Initiative, a public-private partnership formed to support research efforts while growing the region's substantial life sciences industry. Inproteo occupies space in Indiana University's Emerging Technologies Center, a life sciences business incubator located in downtown Indianapolis.